Sign up to access all valuation multiples
Ab&B Bio-Tech Co Ltd JS is a China-based vaccine company dedicated to the research, development, manufacturing and commercialization of innovative vaccines and traditional vaccines adopting new technical methods. Its pipeline included two Core Products, the quadrivalent subunit influenza vaccine and lyophilized human rabies vaccine candidate, along with 11 other vaccine candidates.
2015
580
Last FY Revenue $33.2M
Last FY EBITDA -$23.3M
$2.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Ab&B Bio-Tech Co achieved revenue of $33.2M and an EBITDA of -$23.3M.
Ab&B Bio-Tech Co expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ab&B Bio-Tech Co valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $33.2M | XXX | XXX | XXX |
| Gross Profit | XXX | $19.4M | XXX | XXX | XXX |
| Gross Margin | XXX | 58% | XXX | XXX | XXX |
| EBITDA | XXX | -$23.3M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -70% | XXX | XXX | XXX |
| EBIT | XXX | -$29.3M | XXX | XXX | XXX |
| EBIT Margin | XXX | -88% | XXX | XXX | XXX |
| Net Profit | XXX | -$33.1M | XXX | XXX | XXX |
| Net Margin | XXX | -100% | XXX | XXX | XXX |
| Net Debt | XXX | $86.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of September 5, 2025, Ab&B Bio-Tech Co's stock price is HKD 50 (or $6).
Ab&B Bio-Tech Co has current market cap of HKD 19.6B (or $2.5B), and EV of HKD 20.5B (or $2.6B).
See Ab&B Bio-Tech Co trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.6B | $2.5B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of September 5, 2025, Ab&B Bio-Tech Co has market cap of $2.5B and EV of $2.6B.
Ab&B Bio-Tech Co's trades at 78.9x EV/Revenue multiple, and -112.6x EV/EBITDA.
Equity research analysts estimate Ab&B Bio-Tech Co's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ab&B Bio-Tech Co's P/E ratio is not available.
See valuation multiples for Ab&B Bio-Tech Co and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.5B | XXX | $2.5B | XXX | XXX | XXX |
| EV (current) | $2.6B | XXX | $2.6B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 78.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -112.6x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -89.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -75.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -51.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAb&B Bio-Tech Co's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Ab&B Bio-Tech Co's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ab&B Bio-Tech Co's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Ab&B Bio-Tech Co and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -70% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 44% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 79% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 147% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ab&B Bio-Tech Co acquired XXX companies to date.
Last acquisition by Ab&B Bio-Tech Co was XXXXXXXX, XXXXX XXXXX XXXXXX . Ab&B Bio-Tech Co acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Ab&B Bio-Tech Co founded? | Ab&B Bio-Tech Co was founded in 2015. |
| Where is Ab&B Bio-Tech Co headquartered? | Ab&B Bio-Tech Co is headquartered in Hong Kong. |
| How many employees does Ab&B Bio-Tech Co have? | As of today, Ab&B Bio-Tech Co has 580 employees. |
| Is Ab&B Bio-Tech Co publicy listed? | Yes, Ab&B Bio-Tech Co is a public company listed on HKG. |
| What is the stock symbol of Ab&B Bio-Tech Co? | Ab&B Bio-Tech Co trades under 02627 ticker. |
| When did Ab&B Bio-Tech Co go public? | Ab&B Bio-Tech Co went public in 2025. |
| Who are competitors of Ab&B Bio-Tech Co? | Similar companies to Ab&B Bio-Tech Co include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Ab&B Bio-Tech Co? | Ab&B Bio-Tech Co's current market cap is $2.5B |
| Is Ab&B Bio-Tech Co profitable? | Yes, Ab&B Bio-Tech Co is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
